Fusen Pharmaceutical Co., Ltd.
HHKEX:16520.79
HKD
0.00
(0.00%)
ISIN
KYG370981030
CUSIP
G37098103
Return %
Stock
S&P 500
1Y
11.27
14.20
3Y
-47.33
81.12
5Y
-70.08
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Zhiming Cao
- Full Time Employees
- 1,005
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Urban Industrial Zone Xichuan HN China
- IPO Date
- Jul 11, 2018
- Website
- fusenny.com
- Similar Companies
- Business
- Fusen Pharmaceutical Company Limited engages primarily in the research, development, manufacturing, and sale of pharmaceutical products in the People's Republic of China. Its main product portfolio includes Shuanghuanglian cold medicines such as Shuanghuanglian oral solutions and injections; Sanhuang tablets; heat-clearing and detoxicating oral solutions; nicardipine hydrochloride injections; and other proprietary Chinese medicine and chemical generic drugs. The company focuses on therapeutic areas including respiratory tract diseases, antiviral infection, cardiovascular and cerebrovascular diseases, digestion and metabolism, blood pressure and sugar regulation, tonifying and qi-regulating medicines, anti-anemia, antibacterial and anti-inflammatory treatments, gastrointestinal tract health, and expectorant cough remedies. It serves primarily the domestic Chinese market and operates through subsidiaries including Weihai Rensheng Pharmaceutical and Jiangxi Yongfeng Kangde Pharmaceutical. Founded in 2003 and headquartered in Nanyang, China, Fusen Pharmaceutical targets both traditional Chinese medicine and western medicine markets. Recent significant developments include the National Medical Products Administration of China approving the marketing launch of Enzalutamide soft capsules, developed by its wholly owned subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., for treating non-metastatic and metastatic castration-resistant prostate cancer. Additionally, its Metformin and Ertugliflozin Tablets (I) have been approved and are expected to win bids in China's 11th batch of national centralized drug procurement, enhancing its market presence in diabetes treatments. The company has also successfully included its flagship Shuanghuanglian oral liquid and injection products in the third batch of national centralized procurement of traditional Chinese medicine, covering 31 provinces nationwide, positioning it for revenue growth. In governance, Fusen Pharmaceutical saw leadership changes with the appointment of a new chairman of the Audit Committee and an independent non-executive director as of September 2025. The company forecasts launching at least 20 new products over the next three years targeting key therapeutic areas including anti-infection, cardiovascular, central nervous system, hematology, and oncology to rationalize its product and revenue structure. Fusen Pharmaceutical's operations primarily focus on pharmaceutical manufacturing and sales, encompassing both proprietary Chinese medicines and western medicines, targeting treatment of cold, fever, cardiovascular diseases, anemia, and metabolic disorders. The company maintains a strong domestic footprint with strategic development in national procurement programs and cancer therapy markets, leveraging recent regulatory approvals and bidding successes to drive future growth and diversification in its product offering.